Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
T cell-based immunotherapy, for example, with T cell-recruiting bispecific antibody (bsAb), has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions are still rare. Several tumor immune evasion mechanisms have been reported to counteract...
Saved in:
| Main Authors: | Melanie Märklin, Gundram Jung, Jonas S Heitmann, Helmut R Salih, Martina Svenja Lutz, Boris Klimovich, Stefanie Maurer, Latifa Zekri, Clemens Hinterleitner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/2/e003655.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
by: Hans-Georg Rammensee, et al.
Published: (2020-05-01) -
CLEC12A-directed immunocytokine with target cell–restricted IL-15 activity for treatment of acute myeloid leukemia
by: Boris Klimovich, et al.
Published: (2025-03-01) -
An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2020-12-01) -
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
by: Melanie Märklin, et al.
Published: (2022-03-01) -
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
by: S. M. Greiner, et al.
Published: (2025-07-01)